Getting aggressive on its pipeline
MorphoSys (L:0NDV) recently communicated its plans for its proprietary pipeline, which will help transform the company into a fully integrated biopharmaceutical company. It will be commencing Phase II trials for MOR208 in diffuse large B-cell lymphoma (DLBCL) and chronic lymphocytic leukaemia (CLL) over the next six months, with a Phase III trial in DLBCL expected to start in 2017. MOR202 Phase I/IIa trials in multiple myeloma (MM) are ongoing, with a Phase III expected to commence in 2017.
MOR208: The tip of the spear
Following promising Phase II monotherapy data with MOR208 (anti-CD19 antibody) in DLBCL, MorphoSys plans to initiate an 80-patient Phase II in combination with lenalidomide in second-line relapsed/refractory DLBCL patients in Q415. It also plans to initiate a 120-patient Phase II trial in CLL in combination with idelalisib in BTKi-failures in Q116. A 320-patient pivotal study of MOR208 in combination with bendamustine is expected to commence in 2017.
MOR202: Rejuvenating to relicense
Following promising Phase I/IIa data at ASCO and International Myeloma Workshop (IMW) of MOR202 in MM, MorphoSys plans to continue its 62-patient monotherapy trial, as well as its 24-patient trial of MOR202 in combination with lenalidomide or pomalidomide, with the goal of initiating a Phase III combination trial in 2017.
To Read the Entire Report Please Click on the pdf File Below